Inspire projected an increase of about 26% in its full-year revenue for 2024, landing somewhere between $783 million and $793 million. Inspire Medical Systems FDA Class I recall sleep apnea ...

The FDA has labeled a recall of Inspire Medical Systems, Inc.’s (NYSE:INSP) nerve-stimulating implant for obstructive sleep apnea as Class I, the most serious kind. Inspire initiated a recall of ...

Maple Grove's Inspire Medical Systems uses an electric stimulator similar to a pacemaker to treat sleep apnea, snoring. By Joe Carlson November 19, 2016 at 7:21PM ...

BofA upgrades Inspire Medical to Buy, setting a $255 price target. The company aims for $950 million in 2025 revenue, with a focus on new product launches and expansion.

The FDA has labeled a recall of Inspire Medical Systems, Inc.’s (NYSE:INSP) nerve-stimulating implant for obstructive sleep apnea as Class I, the most serious kind. Inspire initiated a recall of ...

BofA Securities has upgraded Inspire Medical Systems, Inc. (NYSE:INSP) and says the company now falls in the profitable growth category. Inspire Medical is expected to give its 2025 revenue ...

Inspire Medical Systems recalls Model 3028 IPG due to manufacturing defect causing serious health risks. Learn about the FDA Class I recall implications and patient advisories.

The FDA has labeled a recall of Inspire Medical Systems, Inc.’s (NYSE:INSP) nerve-stimulating implant for obstructive sleep apnea as Class I, the most serious kind. Inspire initiated a recall of its ...